Cooley LLP's M&A head Barbara L. Borden
When Horizon Pharma Inc. acquired Vidara Therapeutics International Ltd. for $660 million, it tapped Cooley and its M&A head Barbara L. Borden to spearhead the deal.
Borden’s team included partners Kay Chandler, Sean Clayton, Mark Hrenya and Mischi a Marca; special counsel Barry Graynor, Eric Kauffman and Michelle Lara; and associates Wade Andrews, Ben Beerle, Scott Tanner and Matt Robbins. Partner Jackie Grise (antitrust); partner Natasha Leskovsek (life sciences); of counsel John Steines and associate Michael Baker (tax) provided critical support, according to the firm.
“It was an extremely complex deal, and it was done within a really short time frame,” Borden told WIPL Network. “This is a client I particularly like working with, so that makes it more fun.”
Horizon Pharma is based in Deerfield, Ill., and Vidara is a specialty pharmaceutical company with operations in Dublin, Ireland and the United States. The new company will be organized under the laws of Ireland, which presented interesting challenges during acquisition talks, Borden said. The resulting company will have a portfolio of four products marketed primarily in the United States. The deal, expected to close by mid-2014, positions the company for future acquisitions.
Borden, resident in Cooley’s San Diego office, specializes in mergers and acquisitions, cross-border transactions, joint ventures and other complex transactions and public securities law. She represents strategic and financial buyers and sellers in public and private acquisitions.
Borden said she was attracted to M&A because she enjoys negotiations and likes puzzles. “Deals have a complexity and are like a chess game,” she said. “Successful deals require knowledge about how all the pieces interact, and people can lose track of that.” M&A deals also require a cross-disciplinary aspect, and Borden said she enjoys working with specialists in other practice areas.